Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and Relatlimab in LAG-3+ MMR-d Tumors After Anti-PD-1/PD-L1 Therapy
NCT06400264Phase 2Withdrawn
- Sponsor
- National Cancer Institute
- Start
- Feb 2022
- Primary completion
- Jan 2023
- Modality
- Immune Checkpoint Inhibitors
01
Overview
A Phase 2 trial of relatlimab in solid tumor, lymphoma, multiple myeloma (MM), sponsored by National Cancer Institute. Planned start Feb 2022; status: withdrawn.
02
Drugs
relatlimab
03
Conditions
solid tumorlymphomamultiple myeloma (MM)
Beyond the preview
Go deeper on NCT06400264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06400264.